和誉-B旗下研发的集落刺激因子1受体抑制剂Pimicotinib迎来重要里程碑——美国食品药品监督管理局（FDA）已正式受理其新药申请。该突破性进展标志着这款针对自身免疫性疾病治疗的创新药物正式进入FDA审评流程，为全球患者带来新的治疗希望。
和誉-B旗下研发的集落刺激因子1受体抑制剂Pimicotinib迎来重要里程碑——美国食品药品监督管理局（FDA）已正式受理其新药申请。该突破性进展标志着这款针对自身免疫性疾病治疗的创新药物正式进入FDA审评流程，为全球患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.